Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis
This study has identified PPP1R15A as a novel target for osteoclast differentiation, and genetic inhibition or allosteric inhibitors of PPP1R15A, such as Sephin1, can be used to treat osteoporosis. This study revealed that PPP1R15A expression was increased in osteoporosis in both human and mice. Inhibition of PPP1R15A by specific knockdown or an allosteric inhibitor Sephin1 mitigated murine osteoclast formation in vitro and attenuated ovariectomy-induced osteoporosis in vivo. PPP1R15A inhibition also suppressed pathogenic osteoclastogenesis in CD14+ monocytes from osteoporosis patients. These results identify PPP1R15A as a novel regulator of osteoclastogenesis and a valuable therapeutic target for osteoporosis.PMID:38191913 | DOI:10.1038/s41401-023-01209-0
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Zong-Bao Ding Yan Chen Yu-Rong Zheng Yi-Yuan Wang Wen-de Deng Jie-Huang Zheng Qin Yang Zi-Ye Chen Li-Hong Li Hui Jiang Xiao-Juan Li Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | Genetics | Orthopaedics | Osteoporosis | Study | Translocation